William Blair initiated coverage of Dianthus (DNTH) with an Outperform rating. Dianthus is a clinical-stage biotech company developing DNTH103 for autoimmune neuromuscular indications, notes the analyst, who sees fair value of $47.57 per share.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Dianthus Therapeutics: Promising Prospects in Autoimmune Complement Inhibitor Market with DNTH103 Advancements
- Optimistic Buy Rating for Dianthus Therapeutics Amidst Promising C1s Inhibition Developments
- Buy Rating for Dianthus Therapeutics: Promising Growth Potential of DNTH103 in Neuromuscular Disease Treatment
- Dianthus Therapeutics Announces Board Changes and Elections
- Buy Rating Affirmed for Dianthus Therapeutics: Promising Clinical Potential of DNTH103 in CIDP Treatment